黑色素瘤前哨淋巴结切除术前是否加做SPECT/CT:多中心随机对照试验研究方案
黑色素瘤前哨淋巴结切除(SLNE)假阴性率可高达44%,术前淋巴显像为金标准,SPECT/CT可提供补充解剖定位信息。本方案为多中心、非盲、优效性随机对照试验,比较SPECT/CT辅助SLNE与标准SLNE,主要终点为无远处转移生存。
要点
- SLNE假阴性率可高达44%,是黑色素瘤分期的重要局限
- SPECT/CT可精准定位、识别假阳性并可能减少假阴性
- 主要终点为无远处转移生存,次要终点含总生存与成本等
核心结论
- 研究旨在验证SPECT/CT辅助SLNE较标准SLNE在黑色素瘤患者中是否优效,主要疗效终点为无远处转移生存。
研究设计与样本
- 多中心、非盲、优效性随机对照试验,比较SPECT/CT辅助SLNE与标准SLNE,方案已于2018年9月20日在ClinicalTrials.gov注册(NCT03683550)。
主要发现
- 方案阶段尚未报告结果;背景指出SLNE假阴性率可高达44%,SPECT/CT优势包括准确解剖定位、识别假阳性、减少假阴性和改变手术方式。
关键数值与推荐
- 主要疗效终点为无远处转移生存;次要终点包括总生存、无病生存、随访期内局部复发率(即前哨淋巴结假阴性率)、阳性前哨淋巴结数(敏感性、假阳性率)、并发症率、生活质量、质量调整生命年、住院天数和住院总费用。
临床怎么用
- 若试验证实优效,黑色素瘤患者SLNE术前可考虑加做SPECT/CT以改善淋巴结定位与分期准确性。
局限性
- 本文为研究方案,尚无疗效与安全性结果;试验为非盲设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma has become a growing interdisciplinary problem in public health worldwide. According to the World Health Organization, the incidence of melanoma is increasing faster than any other cancer in the world. Because melanoma metastasizes early into the regional lymph nodes, sentinel lymph node excision (SLNE) is included in the current American Joint Committee of Cancer guidelines. However SLNE of melanoma has a high false-negative rate of up to 44%. METHODS: The gold standard for detection and extirpation of the sentinel lymph node is preoperative lymphoscintigraphy. SPECT/CT provides complementary information: the advantages include accurate anatomical localization, identification of false positives, reduction in the number of false negatives, and alteration of the surgical approach. Therefore, sentinel lymph node-SPECT/CT provides valuable information before sentinel lymph node excision and advocates its use in melanoma. We present a multicenter, unblinded superiority randomized controlled trial to compare SPECT/CT-aided SLNE versus standard SLNE in melanoma patients. DISCUSSION: The primary efficacy endpoint is distant metastasis-free survival. Secondary endpoints comprise overall survival, disease-free survival, rate of local relapses within the follow-up period (false-negative rate of sentinel lymph node), number of positive sentinel lymph nodes (sensitivity, false-positive rate), complication rate, quality of life, quality-adjusted life years, inpatient days, and overall costs during hospital stays. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03683550 . Registered on 20 September 2018.
引用
- Stoffels I, Herrmann K, Rekowski J, et al. Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial. Trials. 2019. PMID: 30717811. doi:10.1186/s13063-019-3197-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。